NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient

详细信息    查看全文

• 作者：Ksenia Sevastianova^a ; ^{ksenia.sevastianova@helsinki.fi" class="auth_mail" title="E-mail the corresponding author} ; Jonathan Dean^b ; Ciaran Bannan^a ; Miriam Coghlan^a ; Gillian Farrell^a ; Catherine Murray^a ; Cillian F. De Gascun^b ; Colm Bergin^a ; ^c
• 关键词：ALT ; alanine aminotransferase ; AST ; aspartate aminotransferase ; cART ; combination antiretroviral therapy ; DAA ; direct-acting antiviral ; DDI ; drug&ndash ; drug interaction ; EOTR ; end-of-treatment response ; GT ; genotype ; HCV ; hepatitis C virus ; HIV-1 ; human immunodeficiency virus type 1 ; IFN ; interferon ; INR ; international normalized ratio ; LDV ; ledipasvir ; MELD ; Model for End-Stage Liver Disease ; NS3 ; non-structural protein 3 ; NS5A ; non-structural protein 5A ; NS5B ; non-structural protein 5B ; PI ; pr
• 刊名：Journal of Clinical Virology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：82
• 期：Complete
• 页码：66-69
• 全文大小：1095 K

文摘

Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir + ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.